The Eosinophil Pathology Unit of the Laboratory of Parasitic Diseases (LPD) studies the role of eosinophils in disease development. LPD research contributes to the development of new diagnostic tools and treatments for hypereosinophilic syndromes (HES) and other conditions associated with excess eosinophils, such as parasitic infections.
The Eosinophil Pathology Unit aims to identify and characterize new HES subtypes and test the safety and effectiveness of treatments that target eosinophils or their precursors. LPD scientists also study the role of eosinophils in reactions to treatment with antiparasite drugs. Parasitic infections can cause symptoms and tissue damage similar to those seen in HES, and treatment with antiparasite drugs can increase eosinophil activation as the parasites die off.
LPD scientists are conducting the following eosinophilia clinical studies at the National Institutes of Health Clinical Center in Bethesda, Maryland:
Learn more about the Eosinophil Pathology Unit and the Laboratory of Parasitic Diseases.
Last Updated April 23, 2014